Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

This study is short for BBCAPX and has been registered at clinicaltrials.gov registry with identifier NCT05171660.